Michael L. Maitland

Host Defense Mechanisms Triggered by Microbial Lipoproteins Through Toll-Like Receptors

Hans D. Brightbill, Daniel H. Libraty, Stephan R. Krutzik et al. · Science · 1999 · 1.7K citations

Microbial Pathogens, Nitric Oxide, Innate Immune System +18

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

Julian D. Gillmore, Ed Gane, Jörg Täubel et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text

Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

Michael L. Maitland, George L. Bakris, Henry R. Black et al. · JNCI Journal of the National Cancer Institute · 2010 · 404 citations · Full text

Hypertension, Cardiovascular Pharmacology, Pharmacotherapy +23

Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

Suresh S. Ramalingam, Michael L. Maitland, Paul Frankel et al. · Journal of Clinical Oncology · 2009 · 267 citations

Purpose Vorinostat, Advanced Nsclc, First-line Therapy +12

Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non Small-Cell Lung Cancer

Theodore Karrison, Michael L. Maitland, Walter M. Stadler et al. · JNCI Journal of the National Cancer Institute · 2007 · 176 citations · Full text